NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013

    NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013

PR Newswire

FT. MYERS, Fla., April 17, 2013

FT. MYERS, Fla., April 17, 2013 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO) announced today that it plans to release its first quarter 2013 financial
results on Thursday, April 25, 2013.

The Company has scheduled a web-cast and conference call to discuss their Q1
2013 results on Thursday, April 25, 2013 at 11:00 AM EDT. Interested
investors should dial (877) 407-8033 (domestic) and (201) 689-8033
(international) at least five minutes prior to the call and ask for Conference
ID Number 412952. A replay of the conference call will be available until
11:59 PM on May 9, 2013 and can be accessed by dialing (877) 660-6853
(domestic) and (201) 612-7415 (international). The playback conference ID
Number is 412952. The web-cast may be accessed under the Investor Relations
section of our website at or An archive of the
web-cast will be available until 11:59 PM EDT on July 25, 2013.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that
specializes in cancer genetics diagnostic testing, the fastest growing segment
of the laboratory industry. The company's testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, anatomic pathology and molecular genetic testing.

Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,
Irvine, CA, Tampa and Fort Myers, FL. NeoGenomics services the needs of
pathologists, oncologists, other clinicians and hospitals throughout the
United States. For additional information about NeoGenomics, visit 

Interested parties can also access investor relations material from Hawk
Associates at or and from
Zack's Investment Research at or

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements, Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Contact: NeoGenomics, Inc., Steven C. Jones, Director of Investor Relations,
(239) 325-2001,; Hawk Associates, Inc., Ms. Julie
Marshall, (305)-451-1888,
Press spacebar to pause and continue. Press esc to stop.